GCM
ARCT icon

Graham Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Graham Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,334
Closed -$420K – 1054
2023
Q4 		$420K Buy
13,334
+4,788
+56% +$114K 0.01% 639
2023
Q3 		$218K Buy
+8,546
New +$263K 0.01% 831
2021
Q2 		– Sell
-74,262
Closed -$3.07M – 119
2021
Q1 		$3.07M Buy
74,262
+54,262
+271% +$3.23M 0.14% 99
2020
Q4 		$867K Buy
+20,000
New +$1.35M 0.03% 104

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's ARCT Position: Q1 2024 in Review

Graham Capital Management sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 13,334 shares — an estimated $420K sold.

Graham Capital Management first reported a position in ARCT in Q4 2020 and held it in 4 quarters. The position peaked at $3.07M in Q1 2021. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Graham Capital Management reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Graham Capital Management sold 13,334 Arcturus Therapeutics shares in Q1 2024, an estimated $420K.
  • Graham Capital Management first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 4 quarters.
  • Graham Capital Management's Arcturus Therapeutics position peaked at $3.07M in Q1 2021.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Graham Capital Management's 13F filing for Q1 2024, filed 15 May 2024.